Navamedic ASA: Appointment of CFO

08 Dec 2025 07:33 CET

Oslo, 8 December 2025: Navamedic ASA ("Navamedic" or the "Company", OSE ticker:
"NAVA") is pleased to announce that the Company has appointed Nils Ole Krekling
Chief Financial Officer (CFO) of Navamedic ASA, effective 1 January 2026.

Mr. Krekling joins Navamedic from Kongsberg Gruppen ASA, where he currently
serves as Group VP Corporate Development and Head of M&A.

"With extensive experience from both finance and strategy roles, Mr. Krekling
brings valuable expertise that will strengthen our financial leadership and
support our strategic ambitions," says Kathrine Gamborg Andreassen, CEO of
Navamedic.

"I am pleased to join Navamedic as CFO. Navamedic is a well-established
organization with bold ambitions, and I look forward to joining the team and
contributing to the Company's continued financial performance and strategic
development," says Nils Ole Krekling.

For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 680 E-mail:
kathrine@navamedic.com.

About Navamedic
Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, addiction, metabolism and
antibiotics, to empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and
requirements of the countries where we are present. Our local insight and
competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is
headquartered in Oslo, Norway. For more information, please visit
www.Navamedic.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

661427_NAVA_Stock_exchange_announcement_08122025.pdf